Katherine Bach Kalin bought $101k of SLS
director at SELLAS Life Sciences Group, Inc.. 63,400 shares at an average of $1.59, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +15RoleDirector
- +10Trade size$101k at market
- +10Relative to holdingsHoldings up 155%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +54.2%, 3m +171.2%, 6m +408.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-114806, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | POpen-market purchase Common Stock | +63,400 | $1.59 | $101k | 104,400 | Nov 21, 2025 |
Related signals
Other insiders at SELLAS Life Sciences Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | SELLAS Life Sciences Group, Inc. | Robert L Van Nostrand director | $15k 10,000 shares | +96% | |
| 46Moderate | SELLAS Life Sciences Group, Inc. | Jane Wasman director | $34k 20,000 shares | +192% | |
| 39Weak | SELLAS Life Sciences Group, Inc. | Katherine Bach Kalin director | $36k 20,000 shares | +95% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.